Origami Surgical

Origami Surgical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Origami Surgical is a private, commercial-stage medical device company addressing a critical safety and efficiency gap in the rapidly growing robotic surgery market. Its flagship product, StitchKit, is a suture-needle management device that secures needles during transfer into the surgical field, directly tackling the problem of lost surgical sharps (needles), which are considered 'never events' but still occur with significant clinical and financial consequences. With a seasoned leadership team and published clinical evidence supporting its value proposition, the company is positioned to capture market share by improving OR workflow and reducing hospital costs associated with retained surgical items.

Surgery

Technology Platform

StitchKit: a single-use suture-needle management device for securing and transferring needles in robotic and laparoscopic surgery, eliminating exposed needle hand-offs.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The rapid growth of the robotic surgery market (15.7% CAGR) creates a expanding installed base for disposable consumables.
Additionally, hospitals face severe financial penalties for 'never events' like retained surgical items, creating a strong economic incentive to adopt preventative technologies like StitchKit.

Risk Factors

Key risks include commercial execution challenges in penetrating slow-moving hospital procurement systems and potential resistance to changing established surgical workflows.
The company also faces competition risk from larger, entrenched medical device companies that could develop similar solutions.

Competitive Landscape

The direct competitive landscape for dedicated needle-transfer safety devices in robotic surgery appears nascent, giving Origami Surgical a potential first-mover advantage. However, it competes indirectly with the status quo (exposed manual transfer) and faces potential future competition from large robotic platform companies (e.g., Intuitive Surgical) and broad-line surgical device giants (e.g., Medtronic, J&J) that could integrate similar features.